中信建投（601066）表示，公司弹簧圈栓塞辅助支架采用了DFT材料编织工艺，可实现支架通体清晰显 影，助力医生全程精准把控操作，提高术中操作的可见性和安全性，同时产品型号更齐全，可以满足临 床中不同病变的治疗需求。弹簧圈栓塞辅助支架的获批，有望进一步加强公司在神经介入领域的产品管 线布局，完善公司神经介入整体解决方案，助力公司市场份额提升，并保持业绩的快速增长态势。 归创通桥(02190)涨超3%，截至发稿，涨2.49%，报25.52港元，成交额1314.41万港元。 消息面上，据归创通桥官微消息，近日，通桥飞龙颅内动脉瘤栓塞辅助支架获得国家药品监督管理局 (NMPA)批准上市。据介绍，通桥飞龙颅内动脉瘤栓塞辅助支架，主要与栓塞弹簧圈配合使用，专为颅 内神经血管疾病治疗打造，为临床诊疗提供全新高效方案。与市面上的同类产品相比，通桥飞龙血颅内 动脉瘤栓塞辅助支架术中贴壁性、显影性更好，能够提高术中操作的可见性和安全性;同时产品型号更 齐全，可以满足临床中不同病变的治疗需求。 ...

Core Viewpoint - The company is a leading player in the domestic and international neurointervention and peripheral intervention sectors, with a rich product pipeline and several innovative products expected to be approved soon, benefiting from accelerated procurement and import substitution, leading to rapid growth in its internal business. The company is projected to turn profitable for the first time in 2024, with continuous improvement in management efficiency and sales scale expected to enhance profitability [1][4]. Event - Recently, the company's intracranial aneurysm embolization assist stent received approval for market launch from the National Medical Products Administration (NMPA) [1]. Summary of Product Developments - The approval of the embolization assist stent strengthens the company's neurointervention product pipeline, providing a new efficient solution for treating intracranial vascular diseases. The stent utilizes DFT material weaving technology for enhanced visibility and safety during procedures, with a comprehensive range of models to meet various clinical needs [1][3]. Growth Outlook - By 2026, both the neurointervention and peripheral intervention businesses are expected to maintain rapid growth, driven by increased procurement, import substitution, and new product launches. The overseas market is also projected to see significant growth, with an average annual compound growth rate of 87% from 2021 to 2024, continuing into 2025 and 2026 [2][4]. Financial Position - As of the first half of 2025, the company has substantial cash reserves of 2.53 billion yuan, which will support increased investment in product research and academic promotion, as well as potential mergers and acquisitions to solidify its leading position in the industry [2][4]. Product Pipeline - As of August 2025, the company has established a product pipeline of 73 items, with 50 approved by NMPA and several others receiving certifications in various countries. Key products expected to be commercialized soon include a large lumen peripheral thrombectomy catheter and an OCT-guided peripheral plaque directional cutting system [3][4]. Market Dynamics - The neurointervention and peripheral intervention markets have significant growth potential due to low domestic penetration rates and opportunities for import substitution. The company is well-positioned to leverage its experience in centralized procurement to accelerate domestic replacement and maintain rapid growth in its internal business [4][5].